Currently out of the existing stock ratings of Asad Haider, 8 are a HOLD (47.06%), 1 are a SELL (5.88%), 8 are a BUY (47.06%).

Asad Haider

Work Performance Price Targets & Ratings Chart

Analyst Asad Haider, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 92.22% that have a potential upside of 21.03% achieved within 179 days.

Asad Haider’s has documented 38 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BNTX, BioNTech SE at 16-Jan-2026.

Wall Street Analyst Asad Haider

Analyst best performing recommendations are on NAMS (NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES).
The best stock recommendation documented was for NAMS (NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES) at 12/2/2025. The price target of $37 was fulfilled within 1 day with a profit of $1.33 (3.47%) receiving and performance score of 34.7.

Average potential price target upside

of $92.13 (12.58%) on LLY (ELI LILLY AND COMPANY).
of $25.69 (34.1%) on MRK (MERCK MPANY).
of $23.94 (13.46%) on JNJ (JOHNSON & JOHNSON).

BMY Bristol-Myers Squibb Company BNTX BioNTech SE INVA Innoviva JNJ Johnson & Johnson LLY Eli Lilly and Company MRK Merck mpany NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares PCVX Vaxcyte PFE Pfizer RPRX Royalty Pharma Plc

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Tim Anderson (BAML)